TPST Insider Trading Activity and SEC Form 4 Filings
TPST insider trading summary
Over the past 12 months, insiders at Tempest Therapeutics, Inc. (TPST) reported 2 open-market purchases worth $1.0M by 1 insider and no sales on SEC Form 4. Net insider buying was $1.0M.
Latest TPST insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 24, 2026 | Matthew Angel | CEO and President | Buy | $500K (231,482 @ $2.16) |
| Mar 24, 2026 | Matthew Angel | CEO and President | Buy | $500K (231,482 @ $2.16) |
| Aug 12, 2024 | Versant Ventures IV, LLC | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Vantage II GP-GP, LLC | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Side Fund IV, L.P. | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Venture Capital IV, L.P. | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Ventures VI GP, L.P. | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Vantage II, L.P. | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Vantage II GP, L.P. | Insider | Sell | $427K (387,999 @ $1.10) |
| Aug 12, 2024 | Versant Ventures VI GP-GP, LLC | Insider | Sell | $427K (387,999 @ $1.10) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.